Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trainor

Showing results (1161-1170 of 1,242) with videos related to

Pageof 125
Sort By:
Molecular Cancer Therapeutics|May 18, 2005
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicityCharles F Albright, Nilsa Graciani, Wei Han, et al.
Journal of Medicinal Chemistry|March 18, 2005
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potencyGeorge V De Lucca, Ui Tae Kim, Brian J Vargo, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitorsLorin A Thompson, Jianliang Shi, Carl P Decicco, et al.
Leukemia|October 22, 2011
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2A V Purandare, T M McDevitt, H Wan, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization productsJ V Duncia, J B Santella, C A Higley, et al.
Journal of Medicinal Chemistry|November 8, 1996
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western regionC J Ohnmacht, K Russell, J R Empfield, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Journal of Medicinal Chemistry|September 26, 2009
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical developmentMark D Wittman, Joan M Carboni, Zheng Yang, et al.
Canadian Journal of Kidney Health and Disease|May 6, 2022
Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to ActionCatherine M Clase, Elizabeth Dicks, Rachel Holden, et al.
Pageof 125

Showing results (1161-1170 of 1,242) with videos related to

Sort By:
Pageof 125
Molecular Cancer Therapeutics|May 18, 2005
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicityCharles F Albright, Nilsa Graciani, Wei Han, et al.
Journal of Medicinal Chemistry|March 18, 2005
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potencyGeorge V De Lucca, Ui Tae Kim, Brian J Vargo, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitorsLorin A Thompson, Jianliang Shi, Carl P Decicco, et al.
Leukemia|October 22, 2011
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2A V Purandare, T M McDevitt, H Wan, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization productsJ V Duncia, J B Santella, C A Higley, et al.
Journal of Medicinal Chemistry|November 8, 1996
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western regionC J Ohnmacht, K Russell, J R Empfield, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Journal of Medicinal Chemistry|September 26, 2009
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical developmentMark D Wittman, Joan M Carboni, Zheng Yang, et al.
Canadian Journal of Kidney Health and Disease|May 6, 2022
Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to ActionCatherine M Clase, Elizabeth Dicks, Rachel Holden, et al.
Pageof 125